Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 7/20 | 0.48 |
| ▸ | CALML3 | P27482 | 7/20 | 0.42 |
| ▸ | MAOB | P27338 | 11/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | SDHA | P31040 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10152686 | 0.89 | MAOA (0.57) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL10152687 | 0.88 | MAOA (0.44) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL2507042 | 0.88 | MAOA (0.47) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL2450926 | 0.88 | MAOA (0.47) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL13589325 | 0.87 | MAOA (0.43) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL10152690 | 0.87 | MAOB (0.47) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL15827767 | 0.86 | MAOA (0.54) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL13101325 | 0.84 | MAOA (0.50) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL11975453 | 0.83 | MAOA (0.50) | MAOACALML3MAOBLMNAPTGS1 | |
| SCHEMBL13368041 | 0.80 | MAOA (0.54) | MAOACALML3MAOBLMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530646-B2 | Oxazolidinone derivative having 7-membered hetero ring | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2013-09-10 | — | — | US | disclosed |
| US-8148362-B2 | Compound having heterocyclic ring | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20100256355-A1 | OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING | Research Foundation ITSUU Laboratory and Shionogi & Co., Ltd. | 2010-10-07 | — | — | US | disclosed |
| US-20090299059-A1 | Novel Compound Having Heterocyclic Ring | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299059-A1 | Novel Compound Having Heterocyclic Ring | NR0B2, NR2C2, NR0B1 | MAOA 2965/4885CALML3 2152/4885MAOB 2611/4885 |
| US-20100256355-A1 | OXAZOLIDINONE DERIVATIVE HAVING 7-MEMBERED HETERO RING | NR0B2, NR0B1, NR2C2 | MAOA 2966/4885CALML3 2496/4885MAOB 2570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.